TN2009000049A1 - A pyrrolopyrazin as syk-kinase inhibitor - Google Patents

A pyrrolopyrazin as syk-kinase inhibitor

Info

Publication number: TN2009000049A1
Authority: TN; Tunisia
Prior art keywords: pyrrolopyrazin; syk; kinase inhibitor; prodrugs; compound
Prior art date: 2006-09-11

Application number

TN2009000049A

Other languages

English (en)

Inventor

Elizabeth M Allen

Kin T Yu

Timothy A Gillespy

A Zilberstein

Paul Eynott

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-11

Filing date

2009-02-17

Publication date

2010-08-19

2009-02-17 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2010-08-19 Publication of TN2009000049A1 publication Critical patent/TN2009000049A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TN2009000049A 2006-09-11 2009-02-17 A pyrrolopyrazin as syk-kinase inhibitor TN2009000049A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82516806P	2006-09-11	2006-09-11
PCT/US2007/078103 WO2008033798A2 (fr)	2006-09-11	2007-09-11	Inhibiteur de kinases

Publications (1)

Publication Number	Publication Date
TN2009000049A1 true TN2009000049A1 (en)	2010-08-19

Family

ID=39032357

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TN2009000049A TN2009000049A1 (en)	2006-09-11	2009-02-17	A pyrrolopyrazin as syk-kinase inhibitor
TN2009000050A TN2009000050A1 (en)	2006-09-11	2009-02-17	Production method of methane gas from olive mill waste

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TN2009000050A TN2009000050A1 (en)	2006-09-11	2009-02-17	Production method of methane gas from olive mill waste

Country Status (32)

Country	Link
US (2)	US8658649B2 (fr)
EP (1)	EP2094708B1 (fr)
JP (1)	JP5161237B2 (fr)
KR (1)	KR101443056B1 (fr)
CN (2)	CN103804383A (fr)
AR (1)	AR062745A1 (fr)
AU (1)	AU2007296592B8 (fr)
BR (1)	BRPI0716781A2 (fr)
CA (1)	CA2663175C (fr)
CL (1)	CL2007002617A1 (fr)
CO (1)	CO6160236A2 (fr)
CR (1)	CR10636A (fr)
DK (1)	DK2094708T3 (fr)
ES (1)	ES2437318T3 (fr)
GT (1)	GT200900055A (fr)
HN (1)	HN2009000455A (fr)
IL (1)	IL197381A (fr)
MA (1)	MA30781B1 (fr)
MX (1)	MX2009002616A (fr)
MY (1)	MY148107A (fr)
NI (1)	NI200900021A (fr)
NO (1)	NO20091265L (fr)
NZ (1)	NZ575496A (fr)
PE (1)	PE20081372A1 (fr)
PT (1)	PT2094708E (fr)
RU (1)	RU2440352C2 (fr)
TN (2)	TN2009000049A1 (fr)
TW (1)	TWI399379B (fr)
UA (1)	UA94622C2 (fr)
UY (1)	UY30584A1 (fr)
WO (1)	WO2008033798A2 (fr)
ZA (1)	ZA200901073B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE522534T1 (de) *	2008-02-25	2011-09-15	Hoffmann La Roche	Pyrrolopyrazin-kinasehemmer
BRPI0907928A2 (pt)	2008-02-25	2015-07-28	Hoffmann La Roche	Inibidores de pirrolopirazina quinase.
MX2010008198A (es)	2008-02-25	2010-08-23	Hoffmann La Roche	Inhibidores de cinasa de pirrolopirazina.
JP5529049B2 (ja)	2008-02-25	2014-06-25	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼ阻害剤
CN101945877B (zh)	2008-02-25	2013-07-03	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
KR20110009084A (ko) *	2008-03-10	2011-01-27	사노피-아벤티스	눈-관련된 장애의 치료방법
FR2929851B1 (fr)	2008-04-09	2012-11-30	Centre Nat Rech Scient	Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es)	2008-12-03	2010-07-27	Sanofi Aventis	Tratamiento para la glomerulonefritis
MX2011004793A (es) *	2008-12-04	2011-05-30	Sanofi Aventis	Formas cristalinas.
AR074776A1 (es) *	2008-12-18	2011-02-09	Sanofi Aventis	Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders
AR075869A1 (es) *	2009-03-19	2011-05-04	Sanofi Aventis	Sintesis de azaindoles
US9181255B2 (en)	2009-12-23	2015-11-10	Takeda Pharmaceutical Company Limited	Fused heteroaromatic pyrrolidinones as SYK inhibitors
US8518945B2 (en)	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) *	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
TWI496785B (zh)	2010-05-20	2015-08-21	Hoffmann La Roche	吡咯并吡激酶抑制劑
CN103003281A (zh) *	2010-05-20	2013-03-27	弗·哈夫曼-拉罗切有限公司	作为JAK和SYK抑制剂的吡咯并[2，3-b]吡嗪-7-甲酰胺衍生物和它们的用途
EP2441755A1 (fr)	2010-09-30	2012-04-18	Almirall, S.A.	Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2489663A1 (fr)	2011-02-16	2012-08-22	Almirall, S.A.	Composés en tant qu'inhibiteurs de la syk kinase
WO2012177714A1 (fr)	2011-06-22	2012-12-27	Takeda Pharmaceutical Company Limited	Dérivés de 6-aza-isoindolin-1-one substitués
JP6404215B2 (ja) *	2012-08-21	2018-10-10	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｓｙｋ阻害剤としてのピロロ［２，３−ｂ］ピラジン
US9376441B2 (en)	2013-07-31	2016-06-28	Gilead Sciences, Inc.	Substituted pyrrolidines as SYK inhibitors
CN114364798A (zh)	2019-03-21	2022-04-15	欧恩科斯欧公司	用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
CN116969927B (zh) *	2023-06-07	2024-03-19	中南民族大学	一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1141949A (en)	1966-02-23	1969-02-05	Sterling Drug Inc	7-azaindole derivatives
US3992392A (en)	1973-04-27	1976-11-16	The Ohio State University Research Foundation	Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv)	1991-03-27	1991-03-27	Astra Ab	New active compounds
GB9226855D0 (en) *	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
WO1995033748A1 (fr)	1994-06-09	1995-12-14	Smithkline Beecham Corporation	Antagonistes du recepteur de l'endotheline
FR2732969B1 (fr)	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6180643B1 (en)	1996-11-19	2001-01-30	Amgen Inc.	Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6312835B1 (en)	1997-02-13	2001-11-06	Queen's University At Kingston	Luminescent compounds and methods of making and using same
EP0970084B1 (fr)	1997-03-19	2003-06-04	Basf Aktiengesellschaft	Pyrrolo 2,3] pyrimidines et leur utilisation comme inhibiteurs de la tyrosine kinase
WO1998047899A1 (fr)	1997-04-24	1998-10-29	Ortho-Mcneil Corporation, Inc.	Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
CN1264381A (zh)	1997-08-05	2000-08-23	辉瑞产品公司	4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
TR200001079T2 (tr)	1997-10-20	2000-07-21	F.Hoffmann-La Roche Ag	Bisiklik kinaz inhibitörleri.
CA2322487C (fr)	1998-03-06	2010-07-20	Metabasis Therapeutics, Inc.	Nouveaux promedicaments pour composes contenant du phosphore
AU3210799A (en)	1998-04-02	1999-10-25	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
WO1999051596A1 (fr)	1998-04-02	1999-10-14	Merck & Co., Inc.	Antagonistes de l'hormone liberant la gonadotropine (gnrh)
US6673797B1 (en)	1998-05-26	2004-01-06	Chugai Seiyaku Kabushiki Kaisha	Heterocyclic indole derivatives and mono- or diazaindole derivatives
DE69928414T2 (de)	1998-09-18	2006-08-03	Abbott Gmbh & Co. Kg	4-aminopyrrolopyrimidine als kinaseinhibitoren
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
NZ519121A (en)	1999-12-24	2004-05-28	Aventis Pharma Ltd	Azaindoles useful as Syk kinase inhibitors
GB9930698D0 (en) *	1999-12-24	2000-02-16	Rhone Poulenc Rorer Ltd	Chemical compounds
US6770666B2 (en)	1999-12-27	2004-08-03	Japan Tobacco Inc.	Fused-ring compounds and use thereof as drugs
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de)	2000-02-25	2001-08-30	Basf Ag	Verfahren zur Herstellung substituierter Indole
EP1265897A1 (fr)	2000-03-20	2002-12-18	Axys Pharmaceuticals, Inc.	Inhibiteurs de la protease exempte d'amidine
JP2001302667A (ja) *	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2001082930A1 (fr)	2000-05-03	2001-11-08	Tularik Inc.	Agents microbiens a base de pyrazole
AU2001259707A1 (en)	2000-06-14	2001-12-24	Warner Lambert Company	6,5-fused bicyclic heterocycles
WO2002028831A1 (fr)	2000-10-02	2002-04-11	Merck & Co., Inc.	Inhibiteurs de la prenyl-proteine transferase
GB0115109D0 (en) *	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (fr)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthese de composes heterocycliques faisant appel a une technologie micro-onde
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
BR0213562A (pt)	2001-10-26	2004-08-31	Aventis Pharma Inc	Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US20040082365A1 (en) *	2002-07-18	2004-04-29	Celerica Ltd	Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (fr)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines utilisées comme inhibiteurs de kinases
WO2005014543A1 (fr)	2003-08-06	2005-02-17	Japan Tobacco Inc.	Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc
EP2239262A3 (fr) *	2004-07-27	2011-10-19	SGX Pharmaceuticals, Inc.	Composés hétérocycliques annelés comme modulateurs de kinases
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
AU2005304952B2 (en)	2004-11-08	2013-04-04	Baxter Healthcare S.A.	Nanoparticulate compositions of tubulin inhibitors
CA2587926A1 (fr) *	2004-11-22	2006-06-01	Vertex Pharmaceuticals Incorporated	Inhibiteurs bicycliques de rho kinase
US20110112101A1 (en)	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders

2007
- 2007-09-10 CL CL200702617A patent/CL2007002617A1/es unknown
- 2007-09-11 BR BRPI0716781-4A2A patent/BRPI0716781A2/pt not_active IP Right Cessation
- 2007-09-11 DK DK07842207.8T patent/DK2094708T3/da active
- 2007-09-11 MX MX2009002616A patent/MX2009002616A/es active IP Right Grant
- 2007-09-11 ES ES07842207.8T patent/ES2437318T3/es active Active
- 2007-09-11 PE PE2007001220A patent/PE20081372A1/es not_active Application Discontinuation
- 2007-09-11 WO PCT/US2007/078103 patent/WO2008033798A2/fr not_active Ceased
- 2007-09-11 KR KR1020097005040A patent/KR101443056B1/ko not_active Expired - Fee Related
- 2007-09-11 AU AU2007296592A patent/AU2007296592B8/en not_active Ceased
- 2007-09-11 CA CA2663175A patent/CA2663175C/fr not_active Expired - Fee Related
- 2007-09-11 MY MYPI20090720A patent/MY148107A/en unknown
- 2007-09-11 UY UY30584A patent/UY30584A1/es not_active Application Discontinuation
- 2007-09-11 AR ARP070104013A patent/AR062745A1/es not_active Application Discontinuation
- 2007-09-11 TW TW096133786A patent/TWI399379B/zh not_active IP Right Cessation
- 2007-09-11 CN CN201310652393.XA patent/CN103804383A/zh active Pending
- 2007-09-11 NZ NZ575496A patent/NZ575496A/en not_active IP Right Cessation
- 2007-09-11 RU RU2009113615/04A patent/RU2440352C2/ru not_active IP Right Cessation
- 2007-09-11 EP EP07842207.8A patent/EP2094708B1/fr active Active
- 2007-09-11 CN CNA2007800336608A patent/CN101511838A/zh active Pending
- 2007-09-11 JP JP2009538434A patent/JP5161237B2/ja not_active Expired - Fee Related
- 2007-09-11 PT PT78422078T patent/PT2094708E/pt unknown
- 2007-11-09 UA UAA200903417A patent/UA94622C2/ru unknown
2009
- 2009-02-16 ZA ZA2009/01073A patent/ZA200901073B/en unknown
- 2009-02-17 NI NI200900021A patent/NI200900021A/es unknown
- 2009-02-17 TN TN2009000049A patent/TN2009000049A1/fr unknown
- 2009-02-17 TN TN2009000050A patent/TN2009000050A1/fr unknown
- 2009-02-25 CR CR10636A patent/CR10636A/es not_active Application Discontinuation
- 2009-03-03 IL IL197381A patent/IL197381A/en not_active IP Right Cessation
- 2009-03-10 US US12/401,254 patent/US8658649B2/en not_active Expired - Fee Related
- 2009-03-10 GT GT200900055A patent/GT200900055A/es unknown
- 2009-03-10 HN HN2009000455A patent/HN2009000455A/es unknown
- 2009-03-11 CO CO09025278A patent/CO6160236A2/es unknown
- 2009-03-26 NO NO20091265A patent/NO20091265L/no not_active Application Discontinuation
- 2009-04-06 MA MA31765A patent/MA30781B1/fr unknown
2014
- 2014-01-28 US US14/166,396 patent/US20140142110A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP5161237B2 (ja)	2013-03-13
BRPI0716781A2 (pt)	2014-11-18
RU2009113615A (ru)	2010-10-20
AU2007296592A1 (en)	2008-03-20
CO6160236A2 (es)	2010-05-20
AU2007296592B2 (en)	2011-12-15
ZA200901073B (en)	2009-12-30
UA94622C2 (en)	2011-05-25
CR10636A (es)	2009-03-20
MY148107A (en)	2013-02-28
JP2010502767A (ja)	2010-01-28
WO2008033798A3 (fr)	2008-05-15
KR101443056B1 (ko)	2014-09-22
EP2094708A2 (fr)	2009-09-02
TWI399379B (zh)	2013-06-21
IL197381A (en)	2013-11-28
EP2094708B1 (fr)	2013-10-23
AR062745A1 (es)	2008-12-03
US20140142110A1 (en)	2014-05-22
MA30781B1 (fr)	2009-10-01
TW200829590A (en)	2008-07-16
NZ575496A (en)	2011-09-30
WO2008033798A2 (fr)	2008-03-20
NI200900021A (es)	2010-01-29
CA2663175A1 (fr)	2008-03-20
HN2009000455A (es)	2012-02-13
CA2663175C (fr)	2012-03-13
PE20081372A1 (es)	2008-11-27
UY30584A1 (es)	2008-05-02
PT2094708E (pt)	2014-01-07
RU2440352C2 (ru)	2012-01-20
CN101511838A (zh)	2009-08-19
NO20091265L (no)	2009-04-03
CN103804383A (zh)	2014-05-21
US8658649B2 (en)	2014-02-25
KR20090063214A (ko)	2009-06-17
IL197381A0 (en)	2009-12-24
TN2009000050A1 (en)	2010-08-19
GT200900055A (es)	2010-07-28
MX2009002616A (es)	2009-03-24
US20100035884A1 (en)	2010-02-11
AU2007296592B8 (en)	2012-01-12
DK2094708T3 (da)	2014-01-27
CL2007002617A1 (es)	2008-05-16
ES2437318T3 (es)	2014-01-10

Publication	Publication Date	Title
TN2009000049A1 (en)	2010-08-19	A pyrrolopyrazin as syk-kinase inhibitor
MY149512A (en)	2013-09-13	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PT1940839E (pt)	2013-10-10	Inibidores de piridopirimidinona pi3k alfa
WO2006123113A3 (fr)	2007-01-04	Composes chimiques
MX2009000884A (es)	2009-06-05	Derivados de piridizinona.
PH12012502057A1 (en)	2015-09-14	Compounds for inhibiting mitotic progression
MX2009003834A (es)	2009-04-22	Derivados de pirrolidina como inhibidores de iap.
SG179418A1 (en)	2012-04-27	Inhibitors of the hedgehog pathway
NZ585460A (en)	2013-02-22	Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2009016460A8 (fr)	2009-10-15	Composés pyrazoles
MX2010004263A (es)	2010-05-03	Inhibidores de quinasa c-fms.
MX2009011579A (es)	2009-11-11	Pirimidinonas como moduladores de caseina cinasa ii (ck2).
WO2008022286A3 (fr)	2008-04-17	petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
MX2009005691A (es)	2009-08-07	Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
TNSN08191A1 (en)	2009-10-30	Kinase inhibitors
TN2010000038A1 (en)	2011-09-26	Organic compounds
PH12013500695A1 (en)	2017-08-09	Pharmaceutical compositions containing a dgat1 inhibitor
MX2009007260A (es)	2009-07-10	Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
MY151003A (en)	2014-03-31	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
EA200900631A1 (ru)	2009-12-30	Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
MX2008016358A (es)	2009-01-16	Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
TNSN08369A1 (en)	2009-12-29	Benzimidazole derivatives
UA96969C2 (en)	2011-12-26	Acylaminopyrazoles as fgfr inhibitors
MY147188A (en)	2012-11-14	Substituted imidazole compounds as ksp inhibitors
TNSN08242A1 (en)	2009-10-30	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof